Acepodia's ACE1831, an allogeneic gamma delta T cell therapy, has received FDA IND clearance for IgG4-related disease, marking Acepodia's entry into autoimmune disease therapeutics.
Acepodia's ACE1831, an allogeneic gamma delta T cell therapy, has received FDA IND clearance for investigation in IgG4-related disease, marking Acepodia's entry into autoimmune disease treatment.
Acepodia's ACE1831, an allogeneic gamma delta T cell therapy, has received FDA IND clearance for IgG4-related disease, marking Acepodia's entry into autoimmune disease treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.